ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

leniolisib

Also written as “Leniolisib” and “CDZ173”.

Its studies are mostly in Common Variable Immunodeficiency · Primary Immunodeficiency Diseases · Lymphadenopathy, led by 2 companies.

Drug pageLeniolisib: every studyAll 9 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Aug 4, 20169 company-led studies, 4 open or runningNext primary completion: Nov 30, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pharming Group74 open or runningphase 3since Aug 4, 2016Aug 4, 2016Nov 30, 2026phase 3 · NCT05438407
Novartisits history only20 open or runningphase 3since Feb 24, 2015Feb 24, 2015none ahead

Also a collaborator on its studies: Aixial Group, CMIC Co, Ltd. Japan, Fortrea, Laboratory Corporation of America and Axial Biotech.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Pharming Group only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Dec 9, 2015Named leniolisibINNProposed as its International Nonproprietary Name in WHO's List 114 · before, CDZ173
  2. Aug 4, 2016First study: phase 3 study in Activated PI3K-delta SyndromeFirst studyNCT02859727 · 37 enrolled · United States, Belarus, Czechia and more
  3. May 20, 2022Phase 3 study in APDSNCT05438407 · 15 enrolled · United States, France, Japan
  4. Oct 17, 2022Phase 3 study in APDSNCT05693129 · 16 enrolled · United States, Japan, Portugal and more
  5. Nov 21, 2023Phase 3 study in APDS Gene MutationNCT06249997 · 3 planned · Japan
  6. Jul 17, 2024Phase 2 study in Primary Immunodeficiency DiseasesNCT06549114 · 13 enrolled · United States
  7. Mar 12, 2025Phase 2 study in Common Variable ImmunodeficiencyNCT06897358 · 27 enrolled · United States, Spain, United Kingdom
  8. May 8, 2025Phase 2 study in PIDs Linked to PI3KNCT06990529 · 12 enrolled · United States, Spain, United Kingdom

Ahead

  1. Nov 30, 2026Primary completion: phase 3 study in APDSNCT05438407
  2. Jul 9, 2028Primary completion: phase 3 study in APDSNCT05693129
  3. Aug 12, 2029Primary completion: phase 2 study in PIDs Linked to PI3KNCT06990529

TargetBeta

PIK3CD →read by rule
“PI3-kinase p110-delta subunit inhibitor; PI3-kinase p110-delta subunit inhibitor”ChEMBL 37, by rule

Other programs on PIK3CD

ProgramCompanyFurthest phaseStudies
idelalisibruleGilead Sciencesphase 428
duvelisibruleSecuraBiophase 326
gedatolisibrulePfizerphase 39
paxalisibrulekazia-therapeutics-limitedphase 24
roginolisibruleioncturaphase 24

Studies

All 7 Pharming Group leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06990529PIDs Linked to PI3K · United States, Spain, United Kingdom2Active, not recruitingAug 12, 202912
NCT06897358Common Variable Immunodeficiency · United States, Spain, United Kingdom2CompletedAug 12, 202627
NCT06549114Primary Immunodeficiency Diseases · United States2CompletedJun 23, 202613
NCT06249997APDS Gene Mutation · Japan3RecruitingJan 31, 20253
NCT05693129APDS · United States, Japan, Portugal and more3Active, not recruitingJul 9, 202816
NCT05438407APDS · United States, France, Japan3Active, not recruitingNov 30, 202615
NCT02859727Activated PI3K-delta Syndrome · United States, Belarus, Czechia and more3TerminatedJan 30, 202537

How it is read

Names in the registry

  • “Leniolisib”, 6 entries
  • “CDZ173”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.